Consensus statement on the use of clozapine during the COVID-19 pandemic

Dan Siskind, MBBS, PhD; William G. Honer, MD; Scott Clark, MBBS, PhD; Christoph U. Correll, MD; Alkomiet Hasan, MD; Oliver Howes, MD, PhD; John M. Kane, MD; Deanna L. Kelly, PharmD; Robert Laitman, MD; Jimmy Lee, MBBS, MMed; James H. MacCabe, MD, PhD; Nick Myles, MD; Jimmi Nielsen, MD, PhD; Peter F. Schulte, MD, PhD; David Taylor, PhD; Helene Verdoux, MD, PhD; Amanda Wheeler, PhD; Oliver Freudenreich, MD

With the ongoing coronavirus disease 2019 (COVID-19) pandemic, psychiatrists find themselves in the clinical situation of being asked by patients, family members and patient advocacy societies to help ensure access to clozapine as a medication critical for ongoing patient care. To provide clozapine prescribing guidance and facilitate regulatory agencies modifying laboratory monitoring and/or dispensing requirements, an expert advisory subgroup of the Treatment Response and Resistance in Psychosis working group developed the following background, recommendations and rationale as a consensus statement.

Clozapine is the most effective antipsychotic for reducing positive symptoms, hospital admissions and all-cause mortality in patients with treatment-refractory schizophrenia.1-3 Owing to the risk of clozapine-associated severe neutropenia, absolute neutrophil count (ANC) monitoring programs are a prerequisite for clozapine dispensation in most jurisdictions globally.4,5 Region-specific limits on outings and clinical resource constraints during the COVID-19 pandemic may create challenges for patients to access routine clozapine-associated care, including ANC testing required for dispensing. Discontinuing clozapine, especially abruptly, creates significant risk of relapse or exacerbation of severity of illness and needs to be avoided. Given the importance of continued access to clozapine, for the duration of the public health emergency we recommend the following.

Recommendation 1
The frequency of ANC may be reduced to every 3 months, with dispensation of up to a 90-day supply (if it can be safely stored) for people fulfilling all of the following criteria:
• continuous clozapine treatment for > 1 year
• have never had an ANC < 2000/µL (or < 1500/µL if history of benign ethnic neutropenia)
• no safe or practical access to ANC testing

Decisions about ANC monitoring for patients on continuous clozapine treatment for 6–12 months may be made on a case-by-case basis. Irrespective of ANC monitoring, patients on clozapine should continue to receive regular clinical assessments of mental state and review of potential adverse drug reactions, either face-to-face or through telehealth consultations. For patients being initiated on clozapine, adherence to current country-specific protocols for ANC monitoring is suggested for the first 6 months of treatment.

Rationale: Maintaining access to routine ANC monitoring for all patients prescribed clozapine is preferred. However, severe neutropenia (ANC < 500/µL) is rare (9/1000 people started on clozapine), with a case-fatality rate of 2.1%.6 Importantly, severe neutropenia has its peak incidence in the first months after clozapine commencement and declines to negligible levels after 1 year.6

Recommendation 2
For patients on clozapine with any symptoms of infection (including those reported for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], such as cough, fever and chills, sore throat or other flu-like symptoms), an urgent physician assessment including a complete blood count (with ANC) should be obtained. The clinical assessment could take place either in person or by telehealth based on local protocols.

Rationale: Clozapine may be associated with a higher risk of pneumonia, likely due to sialorrhea and aspiration rather than neutropenia.6 Clozapine-associated neutropenia is thought to occur as a result of selective neutrophil toxicity mediated by clozapine N-oxide metabolites,7 or an immune response mediated by a hapten-based mechanism,8 both of which occur early in exposure. There is limited information on the impact of coronaviruses on neutrophils among people taking clozapine; however, viral illnesses are generally associated with neutropenia,9 and as such severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in some patients may be a cause of neutropenia not etiologically related to clozapine exposure.

Recommendation 3
If patients on clozapine become symptomatic with fever and flu-like symptoms, the emergence of signs and symptoms of clozapine toxicity may require clinicians to reduce the dose of clozapine by as much as a half. Continue the lower dose until 3 days after the fever has subsided, then increase clozapine in a stepwise manner to the pre-fever dose. Where available, clozapine levels help facilitate clinical decision-making, particularly after substantial dosage change, inadequate response or unexpected adverse effects.

Rationale: Clozapine levels can increase with acute systemic infection,10 leading to symptoms of acute clozapine toxicity, including sedation, myoclonus and seizures. Patients with respiratory infections in or out of hospital may reduce or cease smoking, also leading to raised clozapine levels.11
Any decisions about changes to clozapine dose and monitoring should be made as part of a well-documented, informed consultation with patients and family/caregivers.

Affiliations: From the Metro South Addiction and Mental Health Service, Brisbane, Australia (Siskind); the University of Queensland, School of Clinical Medicine, Brisbane, Australia (Siskind, Myles); the Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (Honer); the University of Adelaide, School of Medicine, Adelaide, Australia (Clark, Kane); the The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, NY, USA (Correll, Kane); the Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecular Medicine, Hempstead, NY, USA (Correll); Chaniótis University of Medicine and Health Sciences, Athens, Greece (Correll); the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Augsburg, Germany (Hassan); the Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK (Howes, MacCabe); the MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK (Howes); the Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK (Howes); the Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA (Kelly); the Bronx Westchester Medical Group, New York, NY, USA (Laitman); the North Region & Department of Psychiatry, Institute of Mental Health, Singapore (Lee); the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (Lee); the Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen (Nielsen); the Mental Health Service Noord-Holland-Noord, Alkmaar, The Netherlands (Schulte); the South London and Maudsley NHS Foundation Trust, Pharmacy Department, Maudsley Hospital, London, UK (Taylor); the University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Bordeaux, France (Verdoux); the Menzies Health Institute Queensland, Griffith University, Brisbane, Australia (Wheeler); the MGH Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA (Freudenreich); and the Harvard Medical School, Boston, MA, USA (Freudenreich).

Competing interests: W. Honer has received consulting fees or sat on paid advisory boards for the Canadian Agency for Drugs and Technology in Health, AlphaSights, Guidepoint, In Silico, Translational Life Sciences, Otsuka, Lundbeck and Neuron. S. Clark has received an investigator-initiated grant, participated in an advisory and an educational board and received speakers fees from Lundbeck-Otsuka Australia and received an investigator-initiated grant from Janssen-Cilag Australia. C. Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Intracellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a data safety monitoring board for Lundbeck, Supernus, Teva and Takeda. He has received grant support from the Berlin Institute of health, Janssen, the National Institute of Mental Health, Patient Centered Outcomes Research Institute, Takeda and the Thrasher Foundation. He has received royalties from UpToDate and is a stock option holder of LB Pharma. A. Hasan has been on the advisory boards and has received speaker fees from Janssen, Lundbeck and Otsuka. O. Howes reports receiving speaker fees, participating on advisory boards, and/or receiving investigator-initiated funding from manufacturers of antipsychotics, including clozapine. J. Kane declares consulting fees/honoraria from Acadia, Alkermes, Allergan, Eli Lilly, Forum, Genentech, Dainippon Sumitomo, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceutical, Jazz Pharma, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva, as well as grant support from Otsuka, Lundbeck and Janssen. He is also a shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. D. Kelly has served as a consultant for Lundbeck, HLS Therapeutics and Alkermes, and is joint holder of a patent for analytical micro-devices for mental health treatment monitoring (US9581536B2). J. MacCabe has received research grants from, and acted as an unpaid consultant to Lundbeck and Saladas Biomedical. D. Taylor has received research funding from Janssen and Sunovion and lecture payments from Janssen, Lundbeck, Otsuka and Recordati. O. Freudenreich has received a grant from Avanir for a clinical trial involving patients taking clozapine and royalties from UpToDate for the entry on clozapine. No other authors declared competing interests.

DOI: 10.1503/jpn.200061

References

6. de Leon J, Sanz EJ, Norén N, et al. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry 2020;19:120.